Impact of ERK5 on the Hallmarks of Cancer

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Elisabetta Rovida	+ 1720 word(s)	1720	2022-01-06 04:42:53	\|
2	format correct	Catherine Yang	Meta information modification	1720	2022-01-14 09:49:39	\|

This entry is adapted from the peer-reviewed paper 10.3390/ijms20061426

Extracellular signal-regulated kinase 5 (ERK5) belongs to the mitogen-activated protein kinase (MAPK) family that consists of highly conserved enzymes expressed in all eukaryotic cells and elicits several biological responses, including cell survival, proliferation, migration, and differentiation.

ERK5 cancer cell proliferation targeted therapy resistance mechanism BMK1 MAPK7

1. The ERK5 Signaling Pathway

ERK5 (also referred to as big mitogen-activated protein kinase 1, BMK-1) is encoded by the MAPK7 gene and is a member of the MAPK family. ERK5 is ubiquitously expressed in mammalian tissues and cell types, where it is activated by extracellular stimuli, including several growth factors and cellular stresses ^[1]^[2]^[3]^[4]. Human ERK5 protein contains 816 amino acids and consists of an N-terminal kinase domain (78–406 aa) and a unique C-terminal tail (410–816 aa), which harbors an autoinhibitory function ^[5]. The C-terminus also contains a myocyte enhancer factor 2 (MEF-2)-interacting region (440–501 aa) ^[6], a nuclear localization signal (NLS) (505–539 aa), and a transcriptional activation domain (664–789 aa) ^[6], which associate with and activate several transcription factors ^[7]. Activation of ERK5 requires dual phosphorylation of threonine and tyrosine residues within a TEY motif in the activation loop of the kinase domain ^[8]. At this site, ERK5 can be phosphorylated and activated by MEK5, which has a unique specificity for ERK5. Activation by MEK5 induces an open conformation of ERK5, the exposure of the NLS, and the translocation into the nucleus. The latter event is crucial for the proliferative signals induced by ERK5 ^[9]. Besides being phosphorylated at the TEY motif, ERK5 is able to phosphorylate its C-terminal tail on serine and threonine residues. These residues at the C-terminus have also been reported to be phosphorylated by CDK1 and/or ERK1/2 ^[10]. Upstream activators of MEK5–ERK5 are MEKK2 and MEKK3, as well as SRC ^[11], TPL2/COT, RAS, and AKT ^[12]. Known substrates for ERK5 are transcription factors, including c-FOS, c-MYC, Sap-1a and MEF2A, C and D, and other kinases, such as RSK and serum/glucocorticoid-regulated kinase (SGK) (Figure 1) ^[13].

Figure 1. Schematic representation of the MEK5–extracellular signal-regulated kinase 5 (ERK5) pathway with activators and downstream effectors.

2. Sustaining Proliferative Signals

ERK5 plays a well-established role in cell proliferation. Several reports have shown activation of ERK5 in response to several mitogens, including epidermal growth factor (EGF) ^[14], nerve growth factor ^[15], fibroblast growth factor (FGF) ^[16], colony-stimulating factor-1 ^[17], and platelet-derived growth factor (PDGF) ^[18]. ERK5 regulates different phases of the cell cycle. For instance, ERK5 mediates G1/S transition by regulating the expression of cyclin D1. Conversely, ERK5 inhibition decreases serum-induced cyclin D1 expression ^[19]. Furthermore, ERK5 is implicated in G2/M transition and is required for mitotic entry. The induction of G2/M by ERK5 depends on the activation of the transcription factor NF-kB, which in turn upregulates mitosis-promoting genes, such as cyclins B1 and B2 and CDC25B ^[20]^[21].

During the last few years, several studies have demonstrated the critical role of MEK5–ERK5 signaling in cancer cell proliferation and tumorigenesis (Figure 2). The role of ERK5 in prostate cancer (PC) proliferation is well established. Human PC displays aberrant expression of ERK5, with significant upregulation of ERK5 protein in high-grade tumors ^[22]. Increased ERK5 cytoplasmic positivity correlates with Gleason score, bone metastases, and locally advanced disease at diagnosis. Pointing to an important role of nuclear ERK5 in cancer, a subgroup of PC patients shows ERK5 nuclear localization, which correlates with poor disease survival ^[23]. Functionally, expression of a constitutively active form of MEK5 increases the percentage in the S phase of human PC LNCaP cells, leading to enhanced proliferation in vitro ^[22]. Along this line, overexpression of ERK5 in PC3 cells increases proliferation in vitro and xenograft growth in vivo ^[23], whereas ERK5 silencing suppresses PC3 cell proliferation ^[24]. In addition, EGF-mediated ERK5 activation induces proliferation of RWPE-2 and PC3 cells by promoting entry into the S phase through upregulation of cyclins A and E ^[25]. Recently, phthalates have been shown to promote PC3 and 22RV1 PC cell proliferation through activation of ERK5 and p38, linking environmental pollution with ERK5 and cancer ^[26]. The role of microRNA as negative regulators of ERK5 is well documented and implicated in mediating ERK5-dependent PC cell proliferation. MiR-143 inversely correlates with nuclear ERK5 in human PC ^[27] and interferes with ERK5 signaling to abrogate PC progression in mice ^[28]. Similarly, overexpression of miR-143 suppresses proliferation of human bladder cancer T24 and Hela cells in vitro and reduces tumor growth of breast cancer (BC) cells in vivo through downregulation of ERK5 ^[29]^[30]^[31].

Figure 2. Connections between ERK5 and the hallmarks of cancer. Established (bold) and proposed (nonbold) downstream mediators of ERK5 are indicated.

3. Evading Growth Suppressors

Regarding the regulation of p21 by ERK5, it has been shown that activated ERK5 inhibits PML-dependent induction of p21. Using XMD8-92, it was later shown that ERK5 inhibition blocks tumor cell proliferation in vitro and significantly inhibits tumor growth in vivo, demonstrating the efficacy and tolerability of ERK5 targeting for cancer treatment in preclinical models ^[32]. Later on, the same group showed that ERK5-mediated phosphorylation of the tumor suppressor PML induces dissociation by MDM2, downregulating the expression of the p53 tumor suppressor ^[33]. Moreover, based on evidence obtained in MDA-MB-231 breast cancer cells, it was proposed that ERK5 blocks p21 expression via a mechanism that implicates c-MYC-dependent transcriptional regulation of the miR-17-92 cluster ^[34]. Regarding p27, we provided evidence that increased expression of p27 upon ERK5 inhibition is likely mediated by AKT/FOXO4. Indeed, XMD8-92 treatment resulted in the partial block of G1/S transition, decreased phosphorylation of AKT, and increased the level of p27 and nuclear FOXO4 ^[35]. Besides regulating p21 expression, inhibition of either MEK5 or ERK5 reduces RB phosphorylation in melanoma cells ^[36].

Interestingly, a link between ERK5 and the tumor suppressor ataxia telangiectasia mutated (ATM) has been identified. Indeed, in the absence of ERK5, the development of T-cell lymphoma in Atm−/− mice is reduced, revealing a functional interaction between ATM and ERK5 (see also the section “Genome Instability”) ^[37]. Transforming growth factor β (TGF-β) signaling is considered a suppressor of tumor growth at the initial stages of tumorigenesis. Despite ERK5 is a well-established mediator of TGF-β-elicited epithelial-to-mesenchymal transition (EMT), a clear tumor-promoting feature (see the section “Activating Invasion and Metastasis”), there is no evidence of a possible role of ERK5 in the regulation of TGF-β-elicited growth-suppressive effects.

4. Avoiding Immune Destruction

In recent years, several reports have highlighted a link between ERK5 signaling and the ability of tumors to evade the immune system. For instance, in human and mouse leukemic cells, ERK5 silencing downregulates major histocompatibility complex class I (MHC-I) expression at the plasma membrane. Injection of ERK5-silenced tumor cells in syngeneic mice recruits and activates natural killer (NK) cells and induces production of cytokines such as IFNγ and TNFα, which attract new NK cells to the site. This raises an immune response against wild-type tumor cells that attenuates tumorigenesis in vivo ^[38]. Similarly, restoration of miR-17/20a functions in murine breast cancer and colon cancer cells mediates the inhibition of the MEKK2–MEK5–ERK5 pathway, leading to the downregulation of MHC-I (H-2D) molecules expressed on tumor cells and enhancing the antitumor activity of NK cells in vivo ^[39].

Deletion of ERK5 in an established PTEN-deficient mouse model of PC increases T-cell infiltration ^[40]. A transcriptomic analysis revealed upregulation in the prostate of double-knockout mice of the chemokines CCL5 and CXCL10, two potent chemoattractants for T lymphocytes. Consistent with this effect, prostate epithelial and stroma of tumors from double-knockout mice show an increase of a predominantly CD4+ T-cell infiltrate. These data provide a preclinical proof of concept that targeting ERK5 might enhance T-cell infiltrates in PC, with possible implications for exploiting immunotherapy in this cancer type ^[40].

5. Enabling Replicative Immortality

The involvement of ERK5 in replicative immortality in cancer cells has not been reported. However, prolonged treatment of the neuroepithelial neuroblastoma/Ewing sarcoma SK-N-MC cell line with the telomerase inhibitor GRN163 upregulates the expression of miR-143 ^[41], a well-known negative regulator of ERK5 ^[28]. Based on that, we might speculate that ERK5 expression is affected by telomere shortening. On the other hand, cellular senescence, characterized by an irreversible arrest in cell proliferation, is among the biological processes that may prevent cellular immortality ^[42]. No definitive link has been demonstrated showing the role of ERK5 in this biological process. However, microarray data identified ERK5 among the genes responsible for the maintenance, but not onset, of methotrexate-induced cellular senescence in the human colon cancer C85 cell line ^[43].

6. Promoting Tumor Inflammation

ERK5 has been proposed as a mediator of cancer-associated inflammation in epidermal carcinogenesis. In particular, epidermal expression of ERK5 is required to mediate inflammation in the skin ^[44]. Indeed, inactivation of ERK5 in epidermal keratinocytes has been shown to prevent inflammation-driven tumorigenesis, with evidence that ERK5 is critical for the development of skin SCC, one of the most common types of human nonmelanoma skin cancer. The causal relationship between ERK5 and inflammation is further supported by the demonstration that epidermal ERK5 controls the expression of a specific subset of proinflammatory cytokines, including IL-1A, IL-1B, and COX-2. Importantly, suppression of inflammation by ERK5 deletion in neoplastic keratinocytes reduces tumor burden ^[44]. This study demonstrated for the first time that ERK5 in epithelial cells is able to remodel the inflammatory microenvironment to support cancer growth. Consistently, it has recently been shown that the ERK5 inhibitor XMD8-92 reduces mesothelioma tumor growth in vivo and inhibits the expression of inflammasome-related genes, such as Caspase-1, IL-1A, IL-1B, HMGB1, and PYCARD ^[45], although the mechanism of this regulation remains to be determined.

ERK5 has been shown to positively regulate, through its target MEF2C, factors important for monocytic differentiation in human myeloid leukemia cells ^[46]. Recently, Tournier’s group demonstrated that selective ERK5 ablation in macrophages blocks phosphorylation of signal transducer and activator of transcription 3 (STAT3), a transcription factor crucial for macrophage polarity, impairing the growth of melanoma and carcinoma xenografts. Furthermore, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. This study suggests that blocking ERK5 may represent a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression ^[47]. Important clinical implications have emerged from this study. First, the possibility that targeting protumor macrophages via anti-ERK5 therapy appears to be an attractive strategy for cancer treatment. Second, there is the occurrence of a possible synergistic effect between targeted inhibition of ERK5 in macrophages with immune checkpoint inhibitors. This effect is in line with the notion that, in addition to contributing to tumorigenesis, TAM play a critical role in tumor-drug resistance and disease relapse after therapy ^[48].

References

Wang, X.; Tournier, C. Regulation of cellular functions by the ERK5 signalling pathway. Cell. Signal. 2006, 18, 753–760.
Drew, B.A.; Burow, M.E.; Beckman, B.S. MEK5/ERK5 pathway: The first fifteen years. Biochim. Biophys. Acta 2012, 1825, 37–48.
Abe, J.; Kusuhara, M.; Ulevitch, R.J.; Berk, B.C.; Lee, J.D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 1996, 271, 16586–16590.
Suzaki, Y.; Yoshizumi, M.; Kagami, S.; Koyama, A.H.; Taketani, Y.; Houchi, H.; Tsuchiya, K.; Takeda, E.; Tamaki, T. Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: Potential role in cell survival following oxidative insults. J. Biol. Chem. 2002, 277, 9614–9621.
Buschbeck, M.; Hofbauer, S.; Di Croce, L.; Keri, G.; Ullrich, A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep. 2005, 6, 63–69.
Kasler, H.G.; Victoria, J.; Duramad, O.; Winoto, A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol. 2000, 20, 8382–8389.
Morimoto, H.; Kondoh, K.; Nishimoto, S.; Terasawa, K.; Nishida, E. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol. Chem. 2007, 282, 35449–35456.
Mody, N.; Campbell, D.G.; Morrice, N.; Peggie, M.; Cohen, P. An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem. J. 2003, 372, 567–575.
Gomez, N.; Erazo, T.; Lizcano, J.M. ERK5 and Cell Proliferation: Nuclear Localization Is What Matters. Front. Cell Dev. Biol. 2016, 4, 105.
Simões, A.E.; Rodrigues, C.M.; Borralho, P.M. The MEK5/ERK5 signalling pathway in cancer: A promising novel therapeutic target. Drug Discov. Today 2016, 21, 1654–1663.
Barros, J.C.; Marshall, C.J. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J. Cell Sci. 2005, 118, 1663–1671.
Nithianandarajah-Jones, G.N.; Wilm, B.; Goldring, C.E.; Müller, J.; Cross, M.J. ERK5: Structure, regulation and function. Cell. Signal. 2012, 24, 2187–2196.
Hoang, V.T.; Yan, T.J.; Cavanaugh, J.E.; Flaherty, P.T.; Beckman, B.S.; Burow, M.E. Oncogenic signaling of MEK5-ERK5. Cancer Lett. 2017, 392, 51–59.
Kato, Y.; Tapping, R.I.; Huang, S.; Watson, M.H.; Ulevitch, R.J.; Lee, J.D. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998, 395, 713–716.
Shao, Y.; Akmentin, W.; Toledo-Aral, J.J.; Rosenbaum, J.; Valdez, G.; Cabot, J.B.; Hilbush, B.S.; Halegoua, S. Pincher, a pinocytic chaperone for nerve growth factor/TrkA signaling endosomes. J. Cell Biol. 2002, 157, 679–691.
Kesavan, K.; Lobel-Rice, K.; Sun, W.; Lapadat, R.; Webb, S.; Johnson, G.L.; Garrington, T.P. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J. Cell. Physiol. 2004, 199, 140–148.
Rovida, E.; Spinelli, E.; Sdelci, S.; Barbetti, V.; Morandi, A.; Giuntoli, S.; Dello Sbarba, P. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J. Immunol. 2008, 180, 4166–4172.
Rovida, E.; Navari, N.; Caligiuri, A.; Dello Sbarba, P.; Marra, F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J. Hepatol. 2008, 48, 107–115.
Mulloy, R.; Salinas, S.; Philips, A.; Hipskind, R.A. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003, 22, 5387–5398.
Cude, K.; Wang, Y.; Choi, H.J.; Hsuan, S.L.; Zhang, H.; Wang, C.Y.; Xia, Z. Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J. Cell Biol. 2007, 177, 253–264.
Díaz-Rodríguez, E.; Pandiella, A. Multisite phosphorylation of Erk5 in mitosis. J. Cell Sci. 2010, 123, 3146–3156.
Mehta, P.B.; Jenkins, B.L.; McCarthy, L.; Thilak, L.; Robson, C.N.; Neal, D.E.; Leung, H.Y. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003, 22, 1381–1389.
McCracken, S.R.; Ramsay, A.; Heer, R.; Mathers, M.E.; Jenkins, B.L.; Edwards, J.; Robson, C.N.; Marquez, R.; Cohen, P.; Leung, H.Y. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 2008, 27, 2978–2988.
Ramsay, A.K.; McCracken, S.R.; Soofi, M.; Fleming, J.; Yu, A.X.; Ahmad, I.; Morland, R.; Machesky, L.; Nixon, C.; Edwards, D.R.; et al. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br. J. Cancer 2011, 104, 664–672.
Xiong, Y.; Zhang, L.; Wang, T. Phosphorylation of BMK1 induces prostatic carcinoma cell proliferation by promoting entry into the S phase of the cell cycle. Oncol. Lett. 2016, 11, 99–104.
Zhu, M.; Huang, C.; Ma, X.; Wu, R.; Zhu, W.; Li, X.; Liang, Z.; Deng, F.; Wu, J.; Geng, S.; et al. Phthalates promote prostate cancer cell proliferation through activation of ERK5 and p38. Environ. Toxicol. Pharmacol. 2018, 63, 29–33.
Ahmad, I.; Singh, L.B.; Yang, Z.H.; Kalna, G.; Fleming, J.; Fisher, G.; Cooper, C.; Cuzick, J.; Berney, D.M.; Møller, H.; et al. Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br. J. Cancer 2013, 108, 149–154.
Clapé, C.; Fritz, V.; Henriquet, C.; Apparailly, F.; Fernandez, P.L.; Iborra, F.; Avancès, C.; Villalba, M.; Culine, S.; Fajas, L. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 2009, 4, e7542.
Noguchi, S.; Mori, T.; Hoshino, Y.; Maruo, K.; Yamada, N.; Kitade, Y.; Naoe, T.; Akao, Y. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 2011, 307, 211–220.
Zheng, F.; Zhang, J.; Luo, S.; Yi, J.; Wang, P.; Zheng, Q.; Wen, Y. miR-143 is associated with proliferation and apoptosis involving ERK5 in HeLa cells. Oncol. Lett. 2016, 12, 3021–3027.
Zhai, L.; Ma, C.; Li, W.; Yang, S.; Liu, Z. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. Mol. Carcinog. 2016, 55, 1990–2000.
Yang, Q.; Deng, X.; Lu, B.; Cameron, M.; Fearns, C.; Patricelli, M.P.; Yates, J.R., 3rd; Gray, N.S.; Lee, J.D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258–267.
Yang, Q.; Liao, L.; Deng, X.; Chen, R.; Gray, N.S.; Yates, J.R., 3rd; Lee, J.D. BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene 2013, 32, 3156–3164.
Perez-Madrigal, D.; Finegan, K.G.; Paramo, B.; Tournier, C. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell. Signal. 2012, 24, 2360–2368.
Rovida, E.; Di Maira, G.; Tusa, I.; Cannito, S.; Paternostro, C.; Navari, N.; Vivoli, E.; Deng, X.; Gray, N.S.; Esparís-Ogando, A.; et al. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut 2015, 64, 1454–1465.
Tusa, I.; Gagliardi, S.; Tubita, A.; Pandolfi, S.; Urso, C.; Borgognoni, L.; Wang, J.; Deng, X.; Gray, N.S.; Stecca, B.; et al. ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene 2018, 37, 2601–2614.
Granados-Jaén, A.; Angulo-Ibáñez, M.; Rovira-Clavé, X.; Gamez, C.P.; Soriano, F.X.; Reina, M.; Espel, E. Absence of ERK5/MAPK7 delays tumorigenesis in Atm−/− mice. Oncotarget 2016, 7, 74435–74447.
Charni, S.; Aguilo, J.I.; Garaude, J.; de Bettignies, G.; Jacquet, C.; Hipskind, R.A.; Singer, D.; Anel, A.; Villalba, M. ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. J. Immunol. 2009, 182, 3398–3405.
Jiang, H.; Wang, P.; Li, X.; Wang, Q.; Deng, Z.B.; Zhuang, X.; Mu, J.; Zhang, L.; Wang, B.; Yan, J.; et al. Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2. Cancer Immunol. Res. 2014, 2, 789–799.
Loveridge, C.J.; Mui, E.J.; Patel, R.; Tan, E.H.; Ahmad, I.; Welsh, M.; Galbraith, J.; Hedley, A.; Nixon, C.; Blyth, K.; et al. Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis. Cancer Res. 2017, 77, 3158–3168.
Uziel, O.; Yosef, N.; Sharan, R.; Ruppin, E.; Kupiec, M.; Kushnir, M.; Beery, E.; Cohen-Diker, T.; Nordenberg, J.; Lahav, M. The effects of telomere shortening on cancer cells: A network model of proteomic and microRNA analysis. Genomics 2015, 105, 5–16.
Campisi, J. Aging, Cellular Senescence, and Cancer. Annu. Rev. Physiol. 2013, 75, 685–705.
Dabrowska, M.; Skoneczny, M.; Rode, W. Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011, 32, 965–976.
Finegan, K.G.; Perez-Madrigal, D.; Hitchin, J.R.; Davies, C.C.; Jordan, A.M.; Tournier, C. ERK5 is a critical mediator of inflammation-driven cancer. Cancer Res. 2015, 75, 742–753.
Thompson, J.K.; Shukla, A.; Leggett, A.L.; Munson, P.B.; Miller, J.M.; MacPherson, M.B.; Beuschel, S.L.; Pass, H.I.; Shukla, A. Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma. Oncotarget 2017, 9, 293–305.
Wang, X.; Pesakhov, S.; Harrison, J.S.; Danilenko, M.; Studzinski, G.P. ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. J. Cell. Physiol. 2014, 229, 856–867.
Giurisato, E.; Xu, Q.; Lonardi, S.; Telfer, B.; Russo, I.; Pearson, A.; Finegan, K.G.; Wang, W.; Wang, J.; Gray, N.S.; et al. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. Proc. Natl. Acad. Sci. USA 2018, 115, E2801–E2810.
Ruffell, B.; Coussens, L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015, 27, 462–472.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Health Care Sciences & Services

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Elisabetta Rovida

View Times: 378

Update Date: 14 Jan 2022

Table of Contents

Video Upload Options

Confirm